Relmada Therapeutics, Inc. RLMD Deferred Tax Assets, Operating Loss Carryforwards, State and Local
Deferred Tax Assets, Operating Loss Carryforwards, State and Local at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal.
The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards, state and local.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards, state and local?
- Relmada Therapeutics, Inc. (RLMD) reported deferred tax assets, operating loss carryforwards, state and local of $2.72M in Q4 2025.
- How has Relmada Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards, state and local changed year-over-year?
- Relmada Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards, state and local increased by 75.0% year-over-year, from $1.55M to $2.72M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards, state and local?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards, state and local has grown at a -21.9% compound annual growth rate (CAGR), from $9.36M to $2.72M.